SUBSCRIBE
SUBSCRIBE

Ipsen Biopharmaceuticals, Inc.

NEWS
Biotech Beach
The Day In Review: Tercica, Inc. And Ipsen Sign Cross-License Deal
July 19, 2006
 · 
1 min read
Business
Ipsen Joins Pfizer In Breast Cancer Trials
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
September 18, 2021
 · 
19 min read
Policy
Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-submit Following Additional Data Analyses
August 13, 2021
 · 
11 min read
Business
Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
August 2, 2021
 · 
14 min read
ISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity
June 11, 2021
 · 
10 min read
Ipsen Announces the Launch of an Employee Shareholding Plan
June 1, 2021
 · 
3 min read
Business
Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
April 22, 2021
 · 
14 min read
Policy
European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma
March 31, 2021
 · 
13 min read
Drug Development
Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide)
February 22, 2021
 · 
15 min read
Deals
Ipsen Delivered Sales Growth and Margin Expansion in 2020 - Focused on Executing New Strategy and Delivering Financial Objectives in 2021
February 11, 2021
 · 
44 min read
Business
Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs
January 20, 2021
 · 
7 min read
Load More